


November 27<sup>th</sup>, 2017

# CIRM

CALIFORNIA'S STEM CELL AGENCY



**Joint Transition and Science Subcommittee Meeting**  
**Jonathan Thomas, Chairman ICOC**

# Goal

- To identify strategies to sustain the Agency beyond Proposition 71 funding.

# Agenda

- Context
- Citizen-led bond measure in November 2020
- Allocation of remaining research dollars
- Bridge funding
- Other fundraising options/goals

# Context

- At our current rate of drawdown, research funds could now run out as early as 2019.
- The goal is to raise \$200M to continue all of CIRM's programs through calendar year 2020.
- CIRM at a critical stage of its mission:
  - On track to achieve Strategic Plan goals
  - Early successes for curative therapies (Kohn SCID and XCGD)
  - Promising early returns on other fronts (Asterias)
  - Increased industry partnerships

# 2020 Bond Measure

- Citizen-sponsored bond measure November 2020
- Legislative option November 2020
  - Back-up option; will continue to update legislators and constitutional candidates

# Research Budget Allocation


- Presentation by Dr. Maria Millan

# Fundraising Scenario:

Preserves CIRM Value Proposition  
Increases "Shots on Goal" & Pipeline

	2018	2019	2020
<b>CLIN</b>	<b>\$130 M</b>	<b>\$130 M</b>	<b>\$114 M</b> ( Total 58 New Trials)
<b>TRAN</b>	<b>\$30 M</b>	<b>\$25 M</b>	<b>\$40 M</b> (Total 61 New Candidates)
<b>DISC</b>	<b>\$10 M</b>	<b>\$9.25 M</b>	<b>\$20 M</b> (12 additional disc projects)
<b>EDUC</b>	<b>\$750 K</b>	<b>\$0 K</b>	<b>\$15 M</b> (5 New Training Awards)
<b>INFR</b>	<b>ongoing</b>	<b>ongoing</b>	<b>\$16 M</b> (2 New Alpha Clinics)

# Maintaining Momentum and CIRM's Value Proposition



Donations can be directed to:



# Supplemental Fundraising

Given recent successes in the field, donors are interested in co-funding one or many projects

- Criteria
- Will piggy back off GWG recommendations and Board approval